广泛期小细胞肺癌胸部放疗时机与分割方式的临床结局
该回顾性研究纳入492例广泛期小细胞肺癌患者,其中244例接受化疗联合胸部放疗。匹配前后联合治疗均改善总生存、无进展生存和局部无复发生存。化疗6周期内行胸部放疗及超分割放疗(45 Gy/30次)可能是可行方案。
要点
- 化疗联合胸部放疗较单纯化疗改善广泛期小细胞肺癌生存。
- 化疗6周期内行胸部放疗与局部无复发生存延长相关。
- 超分割放疗(45 Gy/30次)可能是可行的治疗选择。
核心结论
- 化疗联合胸部放疗可改善广泛期小细胞肺癌患者的生存。
- 化疗6周期内进行胸部放疗及超分割放疗(45 Gy/30次)可能是可行的治疗方案。
研究设计与样本
- 回顾性研究纳入2010年1月至2019年3月的492例广泛期小细胞肺癌患者,其中244例接受化疗联合胸部放疗。
- 采用倾向性评分匹配减少化疗联合胸部放疗组与单纯化疗组间偏倚,并按诱导化疗周期数将联合组分为4个亚组。
- 引入时间调整生物有效剂量(tBED)进行有效剂量分割计算,采用Kaplan-Meier法和Cox比例风险模型分析。
主要发现
- 匹配前联合治疗组总生存(18.1 vs 10.8个月)、无进展生存(9.3 vs 6.0个月)和局部无复发生存(12.0 vs 6.6个月)均优于单纯化疗组,匹配后结果相似。
- 联合组按放疗时机分组的局部无复发生存中位时间分别为12.7、12.0、12.0和9.0个月。
- 早期胸部放疗有延长无进展生存的趋势(中位10.6 vs 9.8 vs 9.0 vs 7.7个月,p=0.091),但总生存无差异(中位17.6 vs 19.5 vs 17.2 vs 19.0个月,p=0.622)。
- 化疗6周期内接受胸部放疗的患者局部无复发生存延长(p=0.001)。
- 高剂量组(tBED>50 Gy)中对全身治疗达完全缓解和部分缓解的患者总生存(中位27.1 vs 22.7,p=0.026)和无进展生存(中位11.4 vs 11.2,p=0.032)相对较短,但排除接受超分割放疗的患者后上述结果未再现(均p>0.05)。
关键数值与推荐
- 联合治疗组按诱导化疗周期数分为4个亚组,放疗时机分组局部无复发生存中位时间分别为12.7、12.0、12.0和9.0个月。
- 早期胸部放疗的无进展生存中位时间分别为10.6、9.8、9.0和7.7个月(p=0.091),总生存中位时间分别为17.6、19.5、17.2和19.0个月(p=0.622)。
- 化疗6周期内行胸部放疗与局部无复发生存延长相关(p=0.001)。
- 高剂量组(tBED>50 Gy)达完全缓解和部分缓解患者总生存中位27.1 vs 22.7个月(p=0.026),无进展生存中位11.4 vs 11.2个月(p=0.032)。
- 超分割放疗方案为45 Gy分30次。
临床怎么用
- 对广泛期小细胞肺癌患者可考虑化疗联合胸部放疗以改善生存。
- 胸部放疗宜在化疗6周期内进行,超分割放疗(45 Gy/30次)可作为可行选择。
- 高剂量放疗(tBED>50 Gy)对全身治疗缓解患者的生存获益需进一步验证,尤其需排除超分割放疗的影响。
局限性
- 原文未报告研究的局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to assess whether thoracic radiotherapy (TRT) combined with chemotherapy (CHT) showed promising anti-tumour activity in extensive-stage small cell lung cancer (ES-SCLC), to explore practice patterns for the radiation time and dose/fractionation and to identify prognostic factors for patients who would benefit from CHT/TRT. METHODS: A total of 492 ES-SCLC patients were included from January 2010 to March 2019, 244 of whom received CHT/TRT. Propensity score matching was performed to minimize bias between the CHT/TRT and CHT-alone groups. Patients in the CHT/TRT group were categorized into four subgroups based on the number of induction CHT cycles. For effective dose fractionation calculations, we introduced the time-adjusted biological effective dose (tBED). Categorical variables were analysed with chi-square tests and Fisher's exact tests. Kaplan-Meier curves were generated to estimate survival rates using the R-project. Multivariate prognostic analysis was performed with Cox proportional hazards models. RESULTS: Patients who received CHT/TRT experienced improved overall survival (OS) (18.1 vs 10.8 months), progression-free survival (PFS) (9.3 vs 6.0 months) and local recurrence-free survival (LRFS) (12.0 vs 6.6 months) before matching, with similar results after matching. In the CHT/TRT group, the median LRFS times for the groups based on the radiation time were 12.7, 12.0, 12.0, and 9.0 months, respectively. Early TRT had a tendency to prolong PFS (median 10.6 vs 9.8 vs 9.0 vs 7.7 months, respectively, p = 0.091) but not OS (median 17.6 vs 19.5 vs 17.2 vs 19.0 months, respectively, p = 0.622). Notably, patients who received TRT within 6 cycles of CHT experienced prolonged LRFS (p = 0.001). Regarding the radiation dose, patients in the high-dose group (tBED > 50 Gy) who achieved complete response and partial response (CR and PR) to systemic therapy had relatively short OS (median 27.1 vs 22.7, p = 0.026) and PFS (median 11.4 vs 11.2, p = 0.032), but the abovementioned results were not obtained after the exclusion of patients who received hyperfractionated radiotherapy (all p > 0.05). CONCLUSION: CHT/TRT could improve survival for ES-SCLC patients. TRT performed within 6 cycles of CHT and hyperfractionated radiotherapy (45 Gy in 30 fractions) may be a feasible treatment scheme for ES-SCLC patients.
引用
- Han J, Fu C, Li B, et al. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations. Radiat Oncol. 2021. PMID: 33663551. doi:10.1186/s13014-021-01773-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。